Interferon-ε is a tumour suppressor and restricts ovarian cancer
Zoe R. C. Marks(Hudson Institute of Medical Research), Paul J. Hertzog(Hudson Institute of Medical Research), Antony Y. Matthews(Hudson Institute of Medical Research), Cassandra J. Vandenberg(The University of Melbourne), Linden J. Gearing(Hudson Institute of Medical Research), Natasha K. Brockwell(La Trobe University), Penelope M. Webb(QIMR Berghofer Medical Research Institute), Nicole K. Campbell(Hudson Institute of Medical Research), Anna DeFazio(Peter MacCallum Cancer Centre), David D.L. Bowtell(The University of Melbourne), Eveline D. de Geus(Hudson Institute of Medical Research), Elizabeth L. Christie(Peter MacCallum Cancer Centre), Sarah Rosli(Hudson Institute of Medical Research), Nicole A. de Weerd(Hudson Institute of Medical Research), Belinda S. Parker(The University of Melbourne), Maree Bilandzic(Hudson Institute of Medical Research), Nollaig M. Bourke(Trinity College Dublin), Le Ying(Children's Hospital of Chongqing Medical University), Joy Hendley(Peter MacCallum Cancer Centre), Gwo‐Yaw Ho(The University of Melbourne), Sián Fereday(Peter MacCallum Cancer Centre), Niamh E. Mangan(Hudson Institute of Medical Research), Jodee A. Gould(Hudson Institute of Medical Research), Georgie Wray‐McCann(Hudson Institute of Medical Research), Michelle D. Tate(Hudson Institute), San Sui Lim(Hudson Institute of Medical Research), Clare L. Scott(Walter and Eliza Hall Institute of Medical Research), Leanne Bowes(Peter MacCallum Cancer Centre), Iain A. McNeish(Imperial College London), Orla McNally(Royal Women's Hospital), Nadia Traficante(The University of Melbourne), Andrew N. Stephens(Hudson Institute of Medical Research), Matthew J. Wakefield(The University of Melbourne)
Cited by 70
Related Papers
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
<i>BRCA</i> Mutation Frequency and Patterns of Treatment Response in <i>BRCA</i> Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
|Journal of Clinical Oncology|2012|1.2k
ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
|Annals of Oncology|2019|1.2k
Type I and II Endometrial Cancers: Have They Different Risk Factors?
|Journal of Clinical Oncology|2013|833